Tzong-Yow Wu, Wan-Ting Tsai, Kai-Hsiang Chen, Szu-Ting Huang, Chun-Fu Huang, Po-Hsien Kuo, Ming-Jui Tsai, Wang-Da Liu, Kuan-Yin Lin, Yu-Shan Huang, Aristine Cheng, Pao-Yu Chen, Hsin-Yun Sun, Huai-Hsuan Huang, Tai-Chung Huang, Shang-Ju Wu, Ming Yao, Jann-Tay Wang, Wang-Huei Sheng, Chien-Ching Hung, Yee-Chun Chen, Shan-Chwen Chang
BACKGROUND: Patients with hematological malignancies (HM) were at a high risk of developing severe disease from coronavirus disease 2019 (COVID-19). We aimed to assess the clinical outcome of COVID-19 in hospitalized patients with HM. METHODS: Adult patients with HM who were hospitalized with a laboratory-confirmed COVID-19 between May, 2021 and November, 2022 were retrospectively identified. Primary outcome was respiratory failure requiring mechanical ventilation or mortality within 60 days after hospitalization...
March 8, 2024: Journal of Microbiology Immunology and Infection